Overview

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Status:
RECRUITING

Trial end date:
2026-12-28

Target enrollment:

Participant gender:

Summary

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.

Phase:

PHASE3

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Insulin Aspart
Insulin Glargine
insulin icodec